Healthcare Apr 25, 2022 09:30 AM (GMT+8) · EqualOcean
Beijing lingfu Biotechnology Co., Ltd. recently completed a pre-A round of financing of more than 200 million yuan. Guoshou equity led the investment, Junlian capital jointly led the investment, and Chang development capital, Puhua capital, Saifu medicine and other institutions followed the investment. Probe capital acted as the financial adviser. This round of financing is mainly used for the layout of experimental animal resource base and laboratory. Lingfu biology was incubated and established by Beijing Saifu Pharmaceutical Research Institute Co., Ltd., Beijing Renyuan Xinsheng Biotechnology Co., Ltd. and the expert team of experimental animal industry. Previously, lingfu biology has completed nearly 50million yuan of angel round financing. Experimental animals and model animals, as carriers, run through the important links of drug development and are the key support of biomedical industry. The coverage and quality of animal models directly affect the success rate of later clinical trials. Lingfu biology is committed to becoming the first scientific research service provider integrating the whole industrial chain of experimental animals, the whole industrial chain of animal models and high value-added scientific research services in China.